reports
Greenwich LifeSciences Provides Update on Financing Strategy
Greenwich LifeSciences Provides Update on Financing Strategy STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through...
Greenwich LifeSciences Provides Update on Patent Claims Potentially Do...
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data. Statistically significant immune ...
ServisFirst Bancshares, Inc. to Announce First Quarter 2026 Financial ...
ServisFirst Bancshares, Inc. to Announce First Quarter 2026 Financial Results April 20th BIRMINGHAM, Ala., March 25, 2026 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc. (NYSE: SFBS) is scheduled to announce earnings and operating results for the quarter ended March 31, 2026 on April 20, 2026 at 4 p.m. ET. The news release will be available at . ServisFirst Bancshares, Inc. will host a live audio webcast to discuss earnings and results on Monday, April 20, 2026 beginning at 5:15 p.m. ET. The audio webcast can be accessed at . A replay of the call will be available until April 30, 2026. ...
ServisFirst Bancshares Inc: 1 director
A director at ServisFirst Bancshares Inc sold 42,000 shares at 74.500USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-...
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest and most advanced cancer research and treatment...
- Jesse Norcross
Public Storage/Biggest becomes even bigger
Public Storage (PSA) announced last Monday that it is acquiring National Storage Affiliates. The largest self-storage provider in the US is buying the 5th largest. We view this transaction as part of PSA's new strategy, PS4.0, through capturing external growth opportunities. The deal clearly cements Public Storage's leading position in the self-storage sector, where fundamentals are slowly beginning to show signs of improvement while supply is coming down. Nevertheless, with inflation set to ris...
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the upcoming AACR Meeting 2026. Two abstracts and two posters were accepted for presentation. The titles and authors of the abstracts are as follows: Abstract Number: CT138 - Poster Se...
Greenwich LifeSciences Provides Update Showing Continued Reduction in ...
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided a preliminary update showing a continued reduction in the recurrence rate in the fully enrolled, 250 patient, open label non-HLA-A*02 arm of FLAMINGO-01. 6 Month...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
ServisFirst Bancshares, Inc. Declares First Quarter Cash Dividend
ServisFirst Bancshares, Inc. Declares First Quarter Cash Dividend BIRMINGHAM, Ala., March 16, 2026 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc., (NYSE: SFBS) (“ServisFirst”), the holding company for ServisFirst Bank, today announces: At a meeting held on March 16, 2026, its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on April 13, 2026, to stockholders of record as of April 1, 2026. About ServisFirst Bancshares, Inc. ServisFirst Bancshares, Inc. is a bank holding company based in Birmingham, Alabama. Through its subsidiary ServisFirst Bank,...
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 ...
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01. All US Sites Treating Patients with Commercially Manufactured GP2 The Company previously announced that the first thr...
- Jonathan Moreland
XRAY DENTSPLY SIRONA INC.
WAT WATERS CORPORATION
TGL. TECNOGLASS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
SFBS SERVISFIRST BANCSHARES INC
ROCK GIBRALTAR INDUSTRIES INC.
NSP INSPERITY INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MYGN MYRIAD GENETICS INC.
MLAB MESA LABORATORIES INC.
IP INTERNATIONAL PAPER COMPANY
GOGO GOGO INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
CRG CRH PLC
PLBC PLUMAS BANCORP
BWFG BANKWELL FINANCIAL GROUP
HOG HARLEY-DAVIDSON INC.
MPB MID PENN BANCORP INC.
SSP THE E.W. SCRIPPS COMPANY
SONO SONOS
KOS KOSMOS ENERGY LTD.
AVTR AVANTOR
AHCO INC.
CMTV ADAPTHEALTH
FOUR COMMUNITY BANCORP INC. VT
VERX SHIFT4 PAYMENTS
ADV INC.
EOSE VERTEX
CSU INC.
IMNM ADVANTAGE SOLUTIONS INC (A)
GRNT EOS ENERGY ENTERPRISES INC (A)
ACVA CAPITAL SENIOR LIVING
CPNG IMMUNOME
TKNO GRANIT SKOPKE
QSI ACV AUCTIONS INC.
TCBX COUPANG
BLCO ALPHA TEKNOVA
SMRT INC.
KRRO QUANTUM-SI INC
NCDL THIRD COAST BANCSHARES INC
FG BAUSCH + LOMB CORP
LYEL SMARTRENT INC
KORRO BIO INC
NUVEEN CHURCHILL DIRECT LENDING CORP
F AND G ANNUITIES AND LIFE
INC.
LYELL IMMUNOPHARMA INC.
- Jonathan Moreland
SFBS SERVISFIRST BANCSHARES INC
GOGO GOGO INC.
CPS COOPER-STANDARD HOLDINGS INC.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
CRG CRH PLC
ECC EAGLE POINT CREDIT CO INC
BWFG BANKWELL FINANCIAL GROUP
MPB MID PENN BANCORP INC.
THRY THRYV HOLDINGS
CSU CAPITAL SENIOR LIVING
CPNG COUPANG
PTLO PORTILLOS INC
FRST PRIMIS FINANCIAL CORP
CGON CG ONCOLOGY INC
MDRR MEDALIST DIVERSIFIED REIT INC.
FG F AND G ANNUITIES AND LIFE
INC.
Greenwich LifeSciences Provides Update on Increased Patient Screen Rat...
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the increased patient screen rate in FLAMINGO-01. FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year Over the past 6 months, the Comp...
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR A...
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, including two corresponding poster...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate a...
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its cash burn rate and financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.